Form 4: Compass Therapeutics CEO Boosts Stake with $2.11 Million Stock Purchase
Insider Transaction Report
Compass Therapeutics, Inc. CEO and Director Thomas J. Schuetz has acquired 10,000 shares of the company's common stock at a weighted average price of $2.11 per share, increasing his total beneficial ownership to over 6.48 million shares.
Summary
- Thomas J. Schuetz, the Chief Executive Officer and a Director of Compass Therapeutics, Inc. (CMPX), purchased 10,000 shares of the company's common stock.
- The transaction took place on May 27, 2025, at a weighted average purchase price of $2.11 per share, with individual purchases at $2.105 and $2.115 per share.
- Following this acquisition, Mr. Schuetz's total beneficial ownership in Compass Therapeutics, Inc. stands at 6,480,825 shares.
- The purchase was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
- A significant portion of Mr. Schuetz's beneficial ownership includes unvested Restricted Stock Units (RSUs): 150,000 RSUs granted on November 16, 2021; 250,000 RSUs granted on February 8, 2023; and 478,125 RSUs granted on January 9, 2024, all subject to service-based vesting conditions.
Sentiment
Score: 7
Explanation: The purchase of shares by the CEO indicates management's confidence in the company's valuation and future prospects, which is generally a positive signal for investors.
Positives
- The CEO's purchase of 10,000 shares signals management's confidence in the company's current valuation and future prospects.
- The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-planned and systematic approach to insider trading, which can be viewed positively for transparency.
Future Outlook
NA
Management Comments
- The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above.
Industry Context
NA
Stakeholder Impact
- Shareholders may view the CEO's purchase as a positive signal of confidence in the company's future performance and alignment of interests with shareholders.
Key Dates
| Date | Description |
|---|---|
| 2021-11-16 | Grant date for 150,000 unvested Restricted Stock Units (RSUs). |
| 2022-11-15 | First installment vesting date for 150,000 RSUs granted on November 16, 2021. |
| 2023-02-08 | Grant date for 250,000 unvested Restricted Stock Units (RSUs). |
| 2024-01-09 | Grant date for 478,125 unvested Restricted Stock Units (RSUs). |
| 2024-02-08 | First installment vesting date for 250,000 RSUs granted on February 8, 2023. |
| 2025-01-09 | First installment vesting date for 478,125 RSUs granted on January 9, 2024. |
| 2025-05-27 | Date of common stock purchase by Thomas J. Schuetz and filing date of Form 4. |
Recommendation
holdKeywords
Compass Therapeutics, CMPX, Insider Trading, Form 4, Stock Purchase, CEO, Director, Beneficial Ownership, Thomas J. Schuetz, Restricted Stock Units, RSU, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.